Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 (LAG-3) binds to its main ligand MHC Class II (MHC-II), also known as HLA Class II (HLA-II) in humans. …
Immutep and Monash announce first publication detailing how human LAG-3 Binds to MHC Class II
December 16, 2024 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
Taylor confirms Anne Ruston will retain health portfolio in opposition reshuffle
February 17, 2026 - - Latest News -
Minister confirms PBS listing for new cystic fibrosis therapy and funded access to other medicines
February 16, 2026 - - Latest News -
Director pay rises across ASX healthcare sector, but gender balance remains uneven
February 16, 2026 - - Latest News -
Life sciences sector unites to advance women’s leadership at landmark 2026 events
February 16, 2026 - - Latest News -
New imaging agent shows stronger detection of recurrent prostate cancer in head-to-head trial
February 16, 2026 - - Australian Biotech -
Medibank funding expansion signals momentum for Emyria’s mental health model
February 16, 2026 - - Latest News -
IMF pours cold water on fears of US pharmaceutical tariffs as pressures shift to care spending
February 16, 2026 - - Latest News